Name of journal: World Journal of Meta-Analysis

ESPS Manuscript NO: 14681

Columns: Meta-Analysis

**Is the traditional Chinese medicine helpful for patients with hematologic malignant diseases? A meta-analysis of randomized controlled trials**

Qian CL *et al.*Traditional Chinese medicine for hematologic malignances

Cheng-Liang Qian, Fei Yan, Yan-Zhi Song, Dong Li, Ke-Zhou Dong, Yi-Min Zhu

**Cheng-Liang Qian,** Department of Traditional Chinese Medicine, Nanjing BenQ Medical Center, Nanjing Medical University, Nanjing 021000, Jiangsu Province, China

**Fei Yan,** Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 021000, Jiangsu Province, China

**Yan-Zhi Song, Dong Li,** Department of Hematology, Nanjing BenQ Medical Center, Nanjing Medical University, Nanjing 021000, Jiangsu Province, China

**Ke-Zhou Dong, Yi-Min Zhu,** Department of Respiration, the 2st Jiangsu Province Hospital of TCM, Nanjing University of Chinese Medicine, Nanjing 021000, Jiangsu Province, China

**Author contributions:** Song YZ conceived and designed the study, searched and selected trials for inclusion, assessed methodological quality of included trials, extracted data, performed the statistical analysis and wrote the review; Qian CL searched trials, selected trials for inclusion, assessed methodological quality of included trials and extracted data; Yan F searched and selected trials for inclusion and wrote the review; Li D, Dong KZ and Zhu YM wrote and revised the review.

**Supported by** The Six Peak Talent Program of Jiangsu Province 2009-47-D.

**Conflict-of-interest:** There is no conflict of interest reported.

**Data sharing:** No.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Dr. Yan-Zhi Song,** Department of Hematology, Nanjing BenQ Medical Center, Nanjing Medical University, 71# Hexi Street, Jianye District, Nanjing 021000, Jiangsu Province, China. yandgics@126.com

**Telephone:** +86-25-52238800-2620

**Fax:** +86-25-52238800

**Received:** October 19, 2014

**Peer-review started:** October 21, 2014

**First decision:** December 26, 2014

**Revised:** April 13, 2015

**Accepted:** May 5, 2015

**Article in press:**

**Published online:**

## Abstract

**AIM:** To evaluate the efficacy of traditional Chinese medicine (TCM) for the treatment of hematologic malignant diseases.

**METHODS**: We searched the Cochrane CENTRAL, Pubmed, Embase, Web of Science, AMED, CNKI, Wanfang Platform; China Sinomed and the clinical trial registry web sites and Googlescholar electronically up to June 19th, 2014 and hand searched related publications. Only RCTs researching on whether TCM as the adjuvant treatment improved the effect for hematologic malignant diseases were included. Two reviewers extracted data and evaluated the studies independently. Pooled risk ratios (RR) were calculated as outcome measures. Our primary outcomes were the overall response (OR) rate.

**RESULTS**: We retrieved 13143 references and included 11 RCTs involved 891 participants after screening. Because the non-significant heterogeneity we used the fixed effect model to combine data and TCM had a significantly higher OR and CR (complete response) rates than the control [RR = 1.17, 95%CI (1.10, 1.25), *P* < 0.00001; RR = 1.24, (1.11, 1.37), *P* < 0.0001, respectively]. Only three studies included in the survival rate analysis. We combined them with random effects model and there was no significant difference between the TCM and control arms. Because of the low heterogeneity we used the fixed effect model to combine the non-hematologic AEs data. Our results showed that TCM significantly decreased non-hematologic AEs rates we researched, the gastrointestinal reaction [RR = 0.50 (0.37, 0.68), *P* < 0.0001], liver and/or kidney injury [RR = 0.37 (0.26, 0.53), *P* < 0.00001] and heart injury [RR = 0.24 (0.09, 0.68), *P* = 0.007]. Additionally, TCM had a trend to decrease the infection rate [RR = 0.16 (0.02, 1.12), *P* = 0.07], but not statistically significantly.

**CONCLUSION**: TCM increases OR and CR rates for hematologic malignances and reduces treatment associated serious non-hematologic AEs. Therefore, TCM should be included in the treatment of hematologic malignances.

**Key words**: Hematologic malignant disease; Leukemia; Lymphoma; Chinese medicine

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We pooled all the studies complied to our inclusion criteria that were retrieved by extensively searching the related databases, journals and websites. Our result suggested that adding traditional Chinese medicine (TCM) increased overall response and complete response rates for malignant hematologic diseases treatment. Although it was based on the evidence of low level of GRADE quality, our result demonstrated that TCM reduced treatment associated serious non-hematologic AEs. Furthermore, considering the rare AEs and drugs interactions, TCM should be included in the hematologic malignances treatment, at least for adult acute leukemia.

Qian CL, Yan F, Song YZ, Li D, Dong KZ, Zhu YM. Is the traditional Chinese medicine helpful for patients with hematologic malignant diseases? A meta-analysis of randomized controlled trials. *World J Meta-Anal* 2015; In press

## INTRODUCTION

The incidence and mortality of malignant tumors have increased greatly in recent years[1]. Albeit the treatment methods of malignant diseases progress quickly the general prognosis of this kind of diseases is poor[1]. Whereby the hematologic malignancies have a particular high-grade malignancy and are systemic diseases that are common to involve multiple systems and organs. Hence, the systemic chemotherapy with western medicine becomes the standard treatment of these kind of diseases[2]. However, the same as other malignant diseases, even in nowadays, the response and survival rates are still not ideal[3,4]. As well as the chemotherapy always causes serious adverse effects (AEs), such as III-IV grade bone marrow suppression, serious nausea and vomiting, hepatic and renal dysfunction and heart injury etc. Attempts to improve therapy by intensifying the number of chemotherapeutic agents or their doses lead only to increase side effects[5]. Even the targeted molecular therapy developed in recent years also causes obvious side effects. For example, the rituximab increases the response rate and survival time for B cell lymphoma[6,7], alternatively, it will obviously suppress the bodies’ normal immune response to pathogens for a long period of more than one year. As a result of it, patients who received it are sensitive to infection and sometimes it is fatal[8,9]. And furthermore, in most conditions, these new medicines need to be administered with chemotherapy together not to mention the tumor cells will become resistant to the therapy after treated for a period[10].

On the other hand, many studies reported that adding traditional Chinese medicine (TCM) into the malignant diseases treatment strategy not only increased the response rate but also significantly lowered the treatment associated AEs rate[11-14]. There are a variety of herbs being used in different combinations and forms, such as oral administration and intravenous injection for hematologic malignancies yet. Many randomized controlled studies have shown that TCM as the adjuvant agent improved the malignant hematologic diseases response and reduced the AEs associated with chemotherapy[15]. But most of the published studies were small sample sized and the results were not consensus. So we wrote the meta-analysis to evaluate the efficacy of TCM for the treatment of hematologic malignant diseases.

## MATERIALS AND METHOD

This meta-analysis followed the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) Statement issued in 2009 (Table 1).

***Inclusion criteria***

We only included randomized controlled trials (RCTs) that researched on whether TCM as the adjuvant treatment improved the effect for malignant hematologic diseases. There was no age, sex, race, complicated diseases or language limits of the study. Our primary outcomes were the overall response (OR) rate calculated by summating the complete response (CR), partial response (PR) and stable disease (SD) rates. The survival and serious AEs rates and the change of quality of life were our secondary outcomes. The diagnosis must be confirmed by pathological sections or bone marrow smears.

Since some TCMs for acute promyelocytic leukemia treatment, such as the compound Huang Dai Tablets, have been administered as the primary maintenance treatment, not the adjuvant treatment and their active ingredients has been recognized as Tetraarsenic tetrasulfide we did not include these studies. The efficacy and safety of this kind of TCM is the focus of our next study.

***Searching method***

YS and CQ searched the following databases independently, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, PubMed, Embase, Web of Science, Allied and Alternative Medicine (AMED), Googlescholar, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform; China biomedical literature service system (Sinomed); and the well-known clinical trial registry sites (<http://www.clinicaltrial.gov/>; http://apps.who.int/trialsearch/). The electronic search was up to June 19th, 2014. The detailed searching strategy for PubMed was recorded in Table 2.

We specified three searching themes: First, we searched TCM related words, we used the terms “complementary medicine”, and the free words “tradition or tradition\* or china or chinese or herb or herbal or complement\* or tcm or “zhong yi” or chm or ethno\* or folk or home or indigenous or primitive or materia\* or nosod\* or east or eastern or orient or oriental or Asian or Korea\* or Tibet\* or herbaceous or plant or plants or botan\* or kampo or mongol\* or phytogenic or phytotherapy or alternative; Second, we searched hematologic diseases related words, we used the terms “leukemia” or “lymphoma” or “multiple myeloma”, and the free words “hemotolog\* or anemia or thrombocytopen\* or pancytope\* or “bone marrow” or transplant or “stem cell” or “leukemia or lymphoma or cancer or dysplas\* or malignant or hyperplas\* or hypoplas\* or myelom\* or Hodgkin or non-Hodgkin or blast or blasts or “progression free survival” or “disease free survival” or “overall survival” or OS or PFS or DFS or chemotherapy or (chemical treatment) or radiotherapy or irradia\* or oncolog\* or monoclon\*”; and third, we used the Cochrane highly sensitive search filters to retrieve randomized trials in Medline and Embase[16].

We also hand searched other journals that might publish relative clinical trials, pubmed related articles, reference lists of retrieved articles. Considering there might be some ongoing studies which did not register in the clinical trial registry sites and some finished studies which did not published, we contacted some researchers, relative manufacturers and specialists for further information of unpublished trials. Our study did not set limits of ages, sexes, races, published languages and regions.

***Data extraction, evaluation and analysis***

YS and CQ extracted data from the retrieved studies. Then they independently used the Cochrane Collaboration tool for assessing risk of bias[17] to assess the quality of the trials (Tables 3-24). The tool comprised of seven specific domains (named sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other issues). We only included studies in ‘‘low risk’’ of bias in the randomization sequence generation and did not show high risks in any other domains. We used the funnel plot to detect the publication bias. If it was symmetrical we considered there was no publication bias, or else, we considered there was publication bias. If there was some disagreement between the two authors, they would resolve it by discussion.

We analyzed the included data with the Revman software (Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012). We used the relative risk (RR) to evaluate the outcomes. If there was not significant heterogeneity between the included studies (detected by the *P* value of the *χ*2 test over 0.10 and *I*2 ≤ 25%) we used the Mantel-Haenszel fixed effect model to analyze data. If there was significant heterogeneity (detected by the *P* value was less than 0.10 and/or *I*2 ≥ 50%) we detected if there was clinical heterogeneity. In the condition of absence of clinical heterogeneity we pooled data with random effects model. If *P* ≥ 0.10 and 25% ≤ *I*2 ≤ 50%, we decided to choose the fixed effect or random effects models to combine data by discussion. Considering there might be clinical heterogeneity between different diseases we performed subgroup analyses (studies were divided into four subgroups: the adult acute leukemia, chronic myelogenous leukemia, lymphoma and pediatric acute myeloid leukemia subgroups). We also used sensitivity analyses to assess the association of the quality of included studies and the clinical characteristics. A two-sided *P* value of less than 0.05 was considered as a significant difference. We also used the GRADE grid to evaluate the quality of evidence on the primary outcome.

***Statistical analysis***

Technical appendix, statistical code, and dataset available from the corresponding author at yandgics@126.com. The article was reviewed by the statistician Xiaoxiao Wang. In her opinion, the RR rate was suitable, the heterogeneity of the included articles was effectively detected and the appropriate pooling methods (the random effects model or fixed effect model) was chosen for the systematic review. He also supported using the funnel plot to detect the publication bias.

## RESULTS

We searched 13143 references in total. There were 367 papers retained after we examined the titles and abstracts. We excluded 347 references in the further assessment with the reason of that focused on the solid tumors but not the hematologic malignancies, were not real RCTs, did not report the primary outcome of our study or clearly described the randomization methods, and had other reasons that did not conform our inclusion criteria[18-20]. Finally all the reviewers agreed 11 studies[15,21-35] involved 891 participants should be included for meta-analysis (Figure 1).

***Characteristics of included trials***

The 11 included studies all compared the overall response rate between the addition of TCM or not in the treatment of hematologic malignant diseases, such as acute leukemia, lymphoma, *etc.* 7 studies[15,21,24-31,33,34] researched the effect of adding TCM to the standard treatment for adult acute leukemia patients. Among the 7 studies, Mao Sheng 2007, Chuan Xin 2013, Ji Hong 2011, Rui Rong 2004 and Wen Jiang 2010[26,27,29,30,32,34] focused on acute myeloid leukemia. [Wang, 2007 #18;Wang, 2007 #9;Xu, 2010 #11;Zhu, 2011 #21]The rest two studies did not restrict the type of the acute leukemia (lymphoblastic or non-lymphoblastic). Only one study Chuan Xin 2013[32] focused on pediatric acute myeloid leukemia patients while no study focused on pediatric acute lymphoblastic leukemia patients. Also only one study Xiu Mei 1997[35] focused on lymphoma patients. Two studies (sHai Yan 2007 and sWei Hong 2013)[22,23] focused on chronic myelogenous leukemia patients. But the basic treatment of the two studies were the hydroxyurea and/or a-interferon treatment but not the tyrosine kinase inhibitors which was the standard treatment recently[36]. Hence we did a sensitivity analysis of excluding the two studies. There was not study included was about the multiple myeloma (MM) or myelodysplastic syndrome (MDS). Only the study Dian Rong 2009[15] published one article in English, all of the rest studies were published in Chinese. Only one study reported the quality of life hence we did not analyze this outcome. There was not significant difference in the demographic characteristics of the two treatment groups in the 11 included studies. Details see Table 25

***Quality of included trials***

Five studies (Dian Rong 2009; Ying Fei 2005; Su Juan 2005; Mao Sheng 2007; Rui Rong 2004)[15,21,24-29,31,33] were multi-center double-blind RCT studies. The rest six studies[22,23,30,32,34,35] were single center studies and did not use the blind method. All of the included studies were not large sampled with the largest sample size (Xiu Mei 1997)[35] was 167 and the smallest sample size was 18 (sHai Yan 2007)[22]. All of the included studies did not use the intention to treat strategy to analyze results. There was no other factors influenced the quality of included studies. The funnel plot of the primary outcome was symmetric (Figure 2). Details see Tables 3-24, 26.

***Efficacy analysis***

Studies in both the OR and CR meta-analyses did not show significant heterogeneity so we combined data with the fixed effect model. The efficacy analyses showed the TCM arm had a significantly higher OR rate than the control arm [relative ratio (RR) = 1.17 with a 95% confidential interval (CI): (1.10, 1.25), *P* < 0.00001] (Figure 3). The higher response rate was also statistically significant in the sensitivity analysis of excluding the two chronic myelogenous studies (RR = 1.17, 95%CI: 1.09, 1.26, *P* < 0.00001). As for the CR rate, the TCM arm was significantly higher than the control group as well [RR = 1.24 (1.11, 1.37), *P* < 0.0001] (Figure 4). And also it was not changed in the sensitivity analysis that excluded the two chronic myelogenous leukemia studies [RR = 1.21 (1.08, 1.35), *P* = 0.0007]. However, the Summary of findings (SoF) table showed the quality of the evidence was low (Table 27). There were three studies[15,21,25-27,35] reported the survival rate. The pooled results of the three studies did not show significant difference between the TCM arm and the control arm [RR = 1.22 (0.77, 1.94), *P* = 0.40] (Figure 5). Studies included in this analysis reported the survival rate of different period and the heterogeneity was significant. As a result of it, we used the random effects model to pool data.

***Serious AEs analysis***

Our study demonstrated the TCM arm had a significantly less non-hematologic serious AEs rates in the gastrointestinal reaction [RR = 0.50 (0.37, 0.68), *P* < 0.0001], liver and/or kidney injury [RR = 0.37 (0.26, 0.53), *P* < 0.00001] and heart injury [RR = 0.24 (0.09, 0.68), *P* = 0.007] analyses (Figure 6). Additionally, the TCM showed a trend of reducing the infection rate [RR = 0.16 (0.02, 1.12), *P* = 0.07] but it was not statistically significant (Figure 7). The rates of III-IV grade agranulocytosis and thrombocytosis were not different between adding TCM in the treatment method and not adding it [RR = 0.52 (0.14, 1.84), *P* = 0.31; RR = 0.52 (0.14, 1.91), *P* = 0.33, respectively] (Figure 7). Most of the included studies did not report the myelosuppression recovery time. So we did not analyze this outcome. In the non-hematologic serious AEs analyses, studies were pooled with the fixed effect model while in the hematologic AEs analyses, studies were pooled with the random effects model because of the significant heterogeneity. Because there were only two to three studies included in the serious AEs meta-analyses, we did not perform subgroup analysis to detect the clinical heterogeneity.

## DISCUSSION

Oncologists begin to pay attention to the effect of TCM for the malignant diseases treatment in nowadays. Several meta-analyses revealed that TCM could improve response rate for some kinds of solid tumors[11-13]. There were also several RCTs showed that some TCM could increase the overall response rate and decrease the AEs rate for hematologic malignancies. But the results published were not consistent[15,34]. At the same time there is not large sample sized RCT reported. As is generally accepted, meta-analysis attempts to identify all studies that would meet the eligibility criteria, subjectively assess the validity of the findings of the included studies and systematically present and synthesize the characteristics and findings of the included studies[37]. Therefore, it increases the sample size and reports a more reliable result. In The Oxford 2011 Levels of Evidence Table, meta-analysis of RCT has become the highest level of evidence[38]. In consequence, meta-analysis is a good method to evaluate the efficacy and safety of TCM for hematologic malignancies.

***Response rate of TCM***

Our results showed that TCM significantly increased the OR and CR rates. Although the GRADE SoF tables (Table 27) showed the evidence quality of the two meta-analyses was low and the recommendation strength was weak (data not show), the TCM causes little side effects and it is economical. Furthermore, even though we included studies of different diseases there was not significant heterogeneity in the meta-analyses. So we could pooled data with the fixed effect model which made the result more reliable. Subsequently, it is suggested that TCM, as an adjuvant treatment method, can improve the efficacy of hematologic malignant diseases treatment.

However, there were two studies included in the chronic myelogenous leukemia subgroup prescribed the hydroxyurea or interferon as the fundamental treatment rather than the tyrosine kinase inhibitors which should be the first choice[36] nowadays. We excluded the two studies in the sensitivity analyses and then we got the same result that the TCM arm had significantly higher response rates (both OR and CR) than the control arm. The results of the sensitivity analyses strengthened the evidence that the response rate could be increased by adding TCM for hematologic malignancies. But there was only one study included in the pediatric acute myeloid leukemia and lymphoma subgroups and no studies on MM and MDS. As it was shown in the efficacy forest, the better effect of the TCM was mainly contributed by the adult acute leukemia subgroup. For this reason we concluded TCM can be used as the adjuvant treatment for acute myeloid leukemia and there was in lack of studies on other hematologic malignant diseases, including chronic myelogenous leukemia.

***Survival rate of TCM***

There were only three studies with significantly heterogeneity involved 328 participants included in the survival rate meta-analysis. We did not show the difference between adding the TCM or not for treatment of malignant hematologic diseases. The result might because the small number of included studies was not enough to show a statistical significance or the addition of TCM can not change the survival rate. We need more high quality studies to clarify the problem. As a result of it, the data included was not enough to draw a conclusion of besides increasing the response rates, whether the addition of TCM can further improve patients survival rate.

***Serious AEs rate of TCM***

It is well known in the solid tumors treatment, TCM can decrease the AEs of chemotherapy[39], our results also showed that TCM significantly decreased the serious non-hematologic AEs and had a trend to reduce the serious infection rate. The result enhanced the role of TCM for hematologic malignant diseases treatment. Decreasing the serious non-hematologic AEs makes the chemotherapy safer and improves patients’ tolerance and adherence. This point is especially important for hematologic malignant diseases because most of such patients do not have the opportunity of surgical operation and rely on chemotherapeutic treatment. Additionally, the chemotherapy usually has better effect for hematologic malignant diseases than solid tumors. Infection is the most common cause of death among patients with acute leukemia accounting for up to 75% of mortality[40]. In our study, we showed a trend of reducing infection rate but it was not statistically significant. Since the three included studies all showed better effect of TCM and two were statistically significant we inferred the reason might be there were not enough studies included. More data was needed to confirm whether it was the truth. There were only two studies included in the serious hematologic AEs meta-analyses and we were in need of more studies to clarify this question.

***Comparison with other studies***

Our study result was consistent with several meta-analyses on the solid tumors[11-14]. In the studies, the authors showed that the Chinese herbal medicine (CHM) can increase the response and survival more than one year rates. Among the diseases studied, the non small cell lung cancer (NSCLC) is also sensitive to chemotherapeutic agents that is something like the hematologic malignancies. Our study also showed that TCM increased the response rate but failed to show that TCM increased the survival rate. This might be because there were not enough participants involved in our meta-analysis or the different clinical features of the diseases we researched. In the NSCLC study, authors demonstrated the CHM decreased the morbidity of serious agranulocytosis and thrombocytosis which was not revealed in our study. As well, this might be caused by the lack of studies included or the different clinical features of the diseases. The consistency of our study with other studies strengthened our results.

***Limitation of the meta-analysis***

We have tried our best to make our research more reliable but we still have some limitation. First, none of included studies were performed out of China and all of the included studies except one were published in Chinese. As the funnel plot was symmetric, the publication bias was unavoidable. Second, six of the included studies were small sample sized and did not mention any blindness methods that had the risk of compromising concealment allocation[41]. Third, except the acute leukemia subgroup, there were rare studies of other hematologic malignant diseases included in the meta-analyses. Thus the efficacy result mainly reflected the efficacy of TCM for acute leukemia. According to our result, it was not clear whether the TCM usage had the same efficacy for other hematologic malignant diseases. Finally, all of the included studies were not large sample sized. Only 5 studies used the central randomization method. As a result of it, the quality of evidence of our study was compromised and the GRADE recommendation level was low. Because of these limitations the reliability might be influenced and the results should be interpreted with caution. As there were some limitations, we extensively searched the related databases, publications and websites, strictly screened and evaluated retrieved articles and analyzed the pooled data. Our study assessed the evidence available recently so it is still significant for evaluating the role of TCM for hematologic malignancies.

Because TCM causes little adverse effects, has little interaction with other drugs or treatment methods it can be safely prescribed in most of the malignant diseases treatment. It is especially popular among the complementary and alternative medicine usage in the palliative care of cancer patients[42]. But recently, it plays more important role in the tumor treatment. Our meta-analysis demonstrated that TCM not only had the advantage of reducing the chemotherapy associated serious non-hematologic AEs and had a trend to reduce the serious infection rate, but also significantly increased the response rate. Our result suggests TCM is helpful for hematologic malignant diseases treatment. Although we failed to show a better survival rate of TCM compared with control, we believed to recommend adding TCM to the hematologic malignancies treatment as an adjuvant therapy is reasonable, at least for adult acute leukemia.

***Conclusion and implications for research***

TCM increases the OR and CR rate for acute leukemia treatment and reduced the treatment associated serious non-hematologic AEs. Therefore, we recommend including TCM in the hematologic malignancies treatment, at least for adult acute leukemia treatment.

Except adult acute leukemia, we need more high quality studies on other hematologic malignant diseases, pediatric patients and in other regions apart from China. We are also in need of studies of TCM on the survival, infection and hematologic AEs rates for hematologic malignancies treatment.

**COMMENTS**

***Background***

Albeit as the standard treatment, the chemotherapy always causes serious adverse effects (AEs) and its efficacy is still not satisfactory. Recently, many studies showed that traditional Chinese medicine (TCM) can improve the effect of the standard treatment and reduce the AEs.

***Research frontiers***

In recent years, more and more researchers begin to pay attention to the effect of TCM for malignant diseases. Many studies showed that TCM can increase the efficacy of the standard treatment and decrease the AEs.

***Innovations and breakthroughs***

Although there were many clinical studies published on the TCM for hematologic malignances, as far as we know, there was no systematic review published on this issue. As far as we know, the authors first summarized the evidence now available on it with systematic review and demonstrated a subjective result. The result confirmed the effectiveness of TCM for hematologic malignances and could be used in the clinical practice.

***Application***

The result showed that TCM can increase the OR and CR rates. In addition, TCM also reduced the non-hematologic serious AEs. The authors consider TCM should be used for hematologic malignances treatment.

***Peer-review***

The manuscript is quite interesting.

**REFERENCES**

1 **Epplein M**, Bostick RM, Mu L, Ogino S, Braithwaite D, Kanetsky PA. Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 2613-2617 [PMID: 25277796 DOI: 10.1158/1055-9965.epi-14-0848]

2 **Ramdass B**, Chowdhary A, Koka PS. Hematological malignancies: disease pathophysiology of leukemic stem cells. *J Stem Cells* 2013; **8**: 151-187 [PMID: 24699024 DOI: jsc.2014.8.3/4.151]

3 **Avigan D**, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Hsu KC. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. *Biol Blood Marrow Transplant* 2013; **19**: 1661-1669 [PMID: 24018393 DOI: 10.1016/j.bbmt.2013.08.011]

4 **de Lima M**, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Schmid C. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. *Biol Blood Marrow Transplant* 2014; **20**: 4-13 [PMID: 24018392 DOI: 10.1016/j.bbmt.2013.08.012]

5 **Fisher RI**, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N Engl J Med* 1993; **328**: 1002-1006 [PMID: 7680764 DOI: 10.1056/nejm199304083281404]

6 **Cai Q**, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma. *Ann Hematol* 2014; **93**: 541-556 [PMID: 24375125 DOI: 10.1007/s00277-013-1979-7]

7 **Ujjani C**, Cheson BD. The optimal management of follicular lymphoma: an evolving field. *Drugs* 2013; **73**: 1395-1403 [PMID: 23884816 DOI: 10.1007/s40265-013-0092-5]

8 **Furst DE**, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Ann Rheum Dis* 2012; **71** Suppl 2: i2-45 [PMID: 22460137 DOI: 10.1136/annrheumdis-2011-201036]

9 **Tavazzi E**, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. *Clin Microbiol Infect* 2011; **17**: 1776-1780 [PMID: 22082208 DOI: 10.1111/j.1469-0691.2011.03653.x]

10 **Stolz C**, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. *Leuk Lymphoma* 2009; **50**: 873-885 [PMID: 19373595 DOI: 10.1080/10428190902878471]

11 **Cho WC**, Chen HY. Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis. *Expert Opin Investig Drugs* 2009; **18**: 617-635 [PMID: 19388879 DOI: 10.1517/13543780902855308]

12 **Cho WC**, Chen HY. Clinical efficacy of traditional Chinese medicine as a concomitant therapy for nasopharyngeal carcinoma: a systematic review and meta-analysis. *Cancer Invest* 2009; **27**: 334-344 [PMID: 19212827 DOI: 10.1080/07357900802392683]

13 **Li SG**, Chen HY, Ou-Yang CS, Wang XX, Yang ZJ, Tong Y, Cho WC. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. *PLoS One* 2013; **8**: e57604 [PMID: 23469033 DOI: 10.1371/journal.pone.0057604]

14 **Zhong LL**, Chen HY, Cho WC, Meng XM, Tong Y. The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: a systematic review and meta-analysis. *Complement Ther Med* 2012; **20**: 240-252 [PMID: 22579437 DOI: 10.1016/j.ctim.2012.02.004]

15 **Lu DR**, Li DY, Chen XY, Ye PZ, Tian SD. Clinical research of compound zhebei granules for increasing the therapeutic effect of chemotherapy in refractory acute leukemia patients. *J Tradit Chin Med* 2009; **29**: 190-194 [PMID: 19894383]

16 **Lefebvre C**, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins jpt, green s (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated march 2011). The Cochrane Collaboration, 2011. Available from: URL: www.cochrane-handbook.org

17 **Higgins JPT**, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins jpt, green s (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 510 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: URL: www.cochrane-handbook.org

18 **Seely D**, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. *Integr Cancer Ther* 2012; **11**: 293-303 [PMID: 22019490 DOI: 10.1177/1534735411425484]

19 **Zhu XY**, Zhang XZ, Zhong XY. [Effect of shenqi fuzheng injection for hemopoietic and immune function reconstruction in patients with hematologic malignancies undergoing chemotherapy]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2010; **30**: 205-207 [PMID: 20462054]

20 **Ni H**. Clinical research of integrated chinese and western medicine for multiple myeloma. *An Hui Medicine* 2006: 915-916. Available from: URL: http://ahyx.chinajournal.net.cn/WKB/WebPublication/index.aspx?mid=ahyx

21 **Huang S**. The clinical study of compound granule of thunberg fritillary bulb for improving the survival of refractory acute leukemia patients. *Beijing University Of Chinese Medicine* 2011. Available from: URL: http:// xb.bucm.edu.cn/

22 **Li H**, Wang Q. Clinical research of qu du hua yu formula for treating chronic myeloid leukemia. *Liaoning Journal of Traditional Chinese Medicine* 2007. Available from: URL: http://www.lnzy.cbpt.cnki.net/WKC/WebPublication/index.aspx?mid=lnzy

23 **Pei W**. Curative effect research of combine traditional chinese and western medicine treatment of chronic myelogenous leukemia. *China Journal of Chinese Medicine* 2013: 935-936. Available from: URL: http://zyx.cbpt.cnki.net/WKB/WebPublication/wkTextContent.aspx?colType=4&yt=2010&st=05

24 **Peng S**. Clinical study of qingrejiedukangbai decoction combined with chemotherapy with western medicine treating acute leukemia with hyperactivity of virulent heat-evil. *Hunan University of Chinese Medicine* 2005. Available from: URL: http://www.hnctcm.edu.cn/xueshuqikan/hunanzyydxxb/

25 **Tian S**. Clinical research of compound zhe bei mu granule assit chemotherapy for treating refractory acute leukemia. *Beijing University of Chinese Medicine* 2006. Available from: URL: http:// xb.bucm.edu.cn/

26 **Wang M**, Lang L, Zhao X, Di H, Li Z, Yang S, Hou W, Yan J. Clinical research of yi qi jie du huo xue chinese medicine combined with chemotherapy for treating the micro residual disease of adult aml. *China Practical Medicine* 2007: 101-102. Available from: URL: http://c.wanfangdata.com.cn/Periodical-zglcsyyx.aspx

27 **Wang M**, Yang S, Hou W, Lang L, Yan J, Zhao X, Li Z. Clinical research of the yi qi jie du huo xue chinese medicine combined with chemotherapy for treating adult aml. *Proceedings of the The 8th National conference of integrated Chinese and Western Medicine Hemotology* 2007: 5

28 **Wei YF**, Wang SY, Ren LL. [Efficacy of shenqi fuzheng injection combined with chemotherapy in treatment of acute leukemia and its effect on T-lymphocyte subsets, serum IFN-gamma, IL-10 and IL-2]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2005; **25**: 303-306 [PMID: 15892271]

29 **Xu RR**, Cao F, Liu ZX. [Clinical observation on treatment of acute myelocytic leukemia by supplementing qi, nourishing yin and clearing heat principle]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2004; **24**: 411-414 [PMID: 15199624]

30 **Xu W**, Yang S, Di H, Li Q, Qiao Zi, Jiang Q, Wang J, Liu X, Huo Y, Jia X, Zhao P, Ma Y. Clinical research of shen qi qing re ke li combined with hag chemotherapy for treatment of acute myeloid leukemia. *Proceedings of the National Conference of Integrated Chinese and Western Medicine Hemotology* 2010: 4

31 **Ye F**. Clinical research of zhe bei mu granule reversing the multi-resistance of acute leukemia. *Beijing University of Chinese Medicine* 2006. Available from: URL: http:// xb.bucm.edu.cn/

32 **Zhang C**, Zou X, Li Y. Clinial research of 20 cases of pediatric acute myeloid leukmia treated withtraditional chinese medicine combined with western medicine chemotherapy. *Traditional Chinese Medicinal Research* 2013: 32-33. Available from: URL: http:// www.cqvip.com/QK/96073X/index.asp

33 **Zhang Y**. Clinical research of compound zhe bei mu granules assit chemotherapy to improve the effecacy of acute leukemia treatment. *Beijing University of Chinese Medicine* 2007. Available from: URL: http://xb.bucm.edu.cn/

34 **Zhu J**. Clinical research of hag chemotherapy combined with chinese medicine for elderly acute myeloid leukemia. *Modern Journal of Integrated Traditional Chinese and Western Medicine* 2011: 4637-4638. Available from: URL: http://xdjh.chinajournal.net.cn/WKC/WebPublication/index.aspx

35 **Guo XM**, Li JX, Yang XF. [Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1997; **17**: 325-327 [PMID: 9863121]

36 **NCCN.org**. Chronic myelogenous leukemia. *NCCN Clinical Practice Guidelines in Oncology* (NCCN Guidelines) 2015; Version 1. Available from: URL: http://www.nccn.org/professionals/physician\_gls/pdf/cml.pdf

37 **Green S**, Higgins JPT, Alderson P, Clarke M, Mulrow CD, Oxman AD. Chapter 1: Introduction. In: Higgins jpt, green s (editors), cochrane handbook for systematic reviews of interventions version 5.1.0 (updated march 2011). *The Cochrane Collaboration* 2011. Available from: URL: www.cochrane-handbook.org

38 **OCEBM Levels of Evidence Working Group**. The oxford 2011 levels of evidence. *Oxford Centre for Evidence-Based Medicine*. Available from: URL: http: //wwwcebmnet/indexaspx?o=5653 2011

39 **Ling CQ**, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. *J Integr Med* 2014; **12**: 331-335 [PMID: 25074882 DOI: 10.1016/S2095-4964(14)60038-8]

40 **EJ B**. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background and approaches to management. In: Wingard jr, bowden ra, editors. *Management of Infection in Oncology PatientsLondon: Martin Dunitz* 2003: 71-104

41 **Hills RK**, Gray R, Wheatley K. Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. *J Evid Based Med* 2009; **2**: 196-204 [DOI: 10.1111/j.1756-5391.2009.01023.x]

42 **Hyodo I**, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. *J Clin Oncol* 2005; **23**: 2645-2654 [PMID: 15728227]

**P-Reviewer:** Alshehabi Z, Romero MR **S-Editor:** Ji FF **L-Editor: E-Editor:**

****

**Figure 1 Study selection.**

****

**Figure 2 Funnel plot of the overall response meta-analysis.**

****

**Figure 3 Overall response meta-analysis.**

****

**Figure 4 Complete response meta-analysis.**

****

**Figure 5 Survival rate meta-analysis.**

****

**Figure 6 Non-hematologic serious adverse effects meta-analysis.**

****

**Figure 7 Hematologic serious adverse effects meta-analysis.**

**Table 1 The PRIsMA checklist**

|  |  |  |  |
| --- | --- | --- | --- |
| **Section/topic**  | **Number** | **Checklist item**  | **Reported on page**  |
| **Title**  |  |
| Title  | 1 | Identify the report as a systematic review, meta-analysis, or both.  | 1 |
| **Abstract**  |  |
| Structured summary  | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  | 2 |
| **Introduction**  |  |
| Rationale  | 3 | Describe the rationale for the review in the context of what is already known.  | 3 |
| Objectives  | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  | 3-4 |
| **Methods**  |  |
| Protocol and registration  | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.  |  |
| Eligibility criteria  | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.  | 5 |
| Information sources  | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.  | 5 |
| Search  | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  | 5-6, Table 2 |
| Study selection  | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  | 6-7 |
| Data collection process  | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  | 7 |
| Data items  | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  | 7 |
| Risk of bias in individual studies  | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  | 6-7 |
| Summary measures  | 13 | State the principal summary measures (e.g., risk ratio, difference in means).  | 7 |
| Synthesis of results  | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (*e.g.*, *I*2) for each meta-analysis.  | 7 |

**Table 2 The PubMed searching strategy**

#1 "Complementary Therapies"[Mesh]

#2 Tradition or tradition\* OR china or chinese OR herb or herbal OR complement\* or tcm or “zhong yi” or chm or ethno\*  or folk or home or indigenous or primitive or materia\* or nosod\* or east or eastern or orient or oriental or asian or Korea\* or Tibet\* or herbaceous or plant or plants or botan\* or kampo or mongol\* or phytogenic or phytotherapy or alternative

#3 Medicine or medicinal or medical or remed\* or therapy or therapies or therapeutic or therapeutics or therapist or treat or treatment or drug or drugs

#4 #2 and #3

#5 #1 or #4

#6 Leukemia or lymphoma or “multiple myeloma”[mesh]

#7 Hemotolog\* or anemia or thrombocytopen\* or pancytope\* or “bone marrow” or transplant or “stem cell”

#8 Leukemia OR lymphoma OR cancer OR dysplas\* OR malignant OR hyperplas\* OR hypoplas\* or myelom\* or Hodgkin or non-hodgkin or blast or blasts or “progression free survival” or “disease free survival” or “overall survival” or OS or PFS or DFS or chemotherapy or (chemical treatment) or radiotherapy or irradia\* or oncolog\* or monoclon\*

#9 #7 and #8

#10 #6 or #9

#11 (((((randomized controlled trial[Publication Type]) OR controlled clinical trial[Publication Type]) OR (randomized or placebo[Title/Abstract])) OR drug therapy[MeSH Subheading]) OR (randomly or groups or trial[Title/Abstract])) OR rct

#12 Animals [mh] NOT humans [mh]

#13 #11 not #12

#14 #5 and #10 and #13

#15 (Cancer or carcinoma or sarcoma)[ti]

#16 Carcinoma[mesh] or sarcoma[mesh]

#17 #14 not (#15 or #16)

**Table 3 Characteristics of Dian Rong 2009 study**

|  |  |
| --- | --- |
| Methods | A randomized double blind placebo controlled工multicenter study |
| Participants | Refraetory acute leukemia patients |
| Interventions | TCM group: combine Chinese interventions with standard chemotherapy of western medicineControl group: standard chemotherapy with western medicine |
| Outcomes | The primary outcome: the response rateThe primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 4 Risk assessment of Dian Rong 2009 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: central randomizedComment: probably done. Several studies published by this research group reported reliable randomization method. |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: Unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Low risk | Quote: a double-blind and placebo controlledComment: probably done. Several studies published by this research group reported reliable method to warrant the double blindness |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: mortality and survival time are objective parameter. Subjective judgement can not influent the result. |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 5 Characteristics of Xiu Mei 1997 study**

|  |  |
| --- | --- |
| Methods | A randomized controlled study |
| Participants | Non-Hodgkin lymphoma patients |
| Interventions | TCM group: standard chemotherapy+traditional Chinese medicineControl group: standard chemotherapy |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 6 Risk assessment of Xiu Mei 1997 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: the random sequence produced by rolling the diceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: mortality and survival is an objective parameter. Subjective judgement can not influent the result |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 7 Characteristics of Ji Hong 2011 study**

|  |  |
| --- | --- |
| Methods | A randomized controlled study |
| Participants | Initial treat old AML patients |
| Interventions | TCM group: HAG+TCMControl group: HAG |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 8 Risk assessment of Ji Hong 2011 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: use the random number table to get the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: the response rate is an objective parameter. Subjective judgement can not influent the result |
| Incomplete outcome data (attrition bias)All outcomes | Low risk | Quote: 7 participants in 53 randomized lost to follow-upComment |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 9 Characteristics of Ying Fei 2005 study**

|  |  |
| --- | --- |
| Methods | A multicenter double-blinded randomized controlled study |
| Participants | Initial treat leukemia patients |
| Interventions | TCM group: standard chemotherapy+Shen Qi Fu Zheng YeControl group: standard chemotherapy |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome |

TCM: Traditional Chinese medicine.

**Table 10 Risk assessment of Ying Fei 2005 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: generate randomization sequence by drawing lotsComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: the response rate is an objective parameter Subjective judgement can not influent the result |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 11 Characteristics of Wen Jiang 2010 study**

|  |  |
| --- | --- |
| Methods | A randomized placebo controlled study |
| Participants | Initial treat acute leukemia patients |
| Interventions | TCM group: standard chemotherapy+Shen Qi Qing Re Ke LiControl group: standard chemotherapy |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 12 Risk assessment of Wen Jiang 2010 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: use the random number table to get the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: the response rate is an objective parameter. Subjective judgement can not influent the result |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 13 Characteristics of Su Juan 2005 study**

|  |  |
| --- | --- |
| Methods | A multicenter randomized controlled study |
| Participants | Acute leukemia |
| Interventions | TCM group: standard chemotherapy+tranditional Chinese medicine Qing Re Jie Du Kang Bai FangControl group: standard chemotherapy |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome |

TCM: Traditional Chinese medicine.

**Table 14 Risk assessment of Su Juan 2005 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: use the random number table to get the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: the response rate is an objective parameter. Subjective judgement can not influent the result. |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 15 Characteristics of Mao Sheng 2007 study**

|  |  |
| --- | --- |
| Methods | A multicenter double-blinded randomized placebo controlled study |
| Participants | Acute myeloid leukemia patients with micro residual disease |
| Interventions | TCM group: standard chemotherapy+Yi Qi Jie Du Huo Xue FangControl group: standard chemotherapy |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome |

TCM: Traditional Chinese medicine.

**Table 16 Risk assessment of Mao Sheng 2007 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: use the random number table to get the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: the response rate is an objective parameter. Subjective judgement can not influent the result. |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 17 Characteristics of Rui Rong 2004 study**

|  |  |
| --- | --- |
| Methods | A multicenter double-blinded randomized placebo controlled study |
| Participants | Acute myeloid leukemia |
| Interventions | TCM group: standard chemotherapy+Yi Qi Yang Yin Qing Re FaControl group: standard chemotherapy |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 18 Risk assessment of Rui Rong 2004 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: use the random number table to get the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: the response rate is an objective parameter. Subjective judgement can not influent the result. |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 19 Characteristics of Chuan Xin 2013 study**

|  |  |
| --- | --- |
| Methods | A randomized controlled study |
| Participants | Child acute myeloid leukemia patients |
| Interventions | TCM group: standard chemotherapy+traditional Chiness medicineControl group: standard chemotherapy |
| Outcomes | The primary outcome: the overall response rate The primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 20 Risk assessment of Chuan Xin 2013 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: use the random number table to get the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentionedComment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk | Quote: not mentionedComment: the response rate is an objective parameter. Subjective judgement can not influent the result. |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 21 Characteristics of sWei Hong 2013 study**

|  |  |
| --- | --- |
| Methods | A randomized controlled study |
| Participants | Chronic myeloid leukemia patients |
| Interventions | TCM group: a-interferon or hydroxyurea+traditional Chinese medicineControl group: a-interferon or hydroxyurea |
| Outcomes | The primary outcome: the response rateThe primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 22 Risk assessment of sWei Hong 2013 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: the random number table was used to generate the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentioned Comment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk  | Quote: not mentionedComment: mortality and survival is an objective parameter. Subjective judgement can not influent the result. |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 23 Characteristics of sHai Yan 2007 study**

|  |  |
| --- | --- |
| Methods | A randomized controlled study |
| Participants | Chronic myeloid leukemia patients |
| Interventions | TCM group: hydroxyurea+traditional Chinese medicineControl group: hydroxyurea |
| Outcomes | The primary outcome: the response rateThe primary safety outcome:  |

TCM: Traditional Chinese medicine.

**Table 24 Risk assessment of sHai Yan 2007 study**

|  |  |  |
| --- | --- | --- |
| **Bias** | **Authors’ judgement** | **Support for judgement** |
| Random sequence generation (selection bias) | Low risk | Quote: the random number table was used to generate the allocation sequenceComment: probably done |
| Allocation concealment (selection bias) | Unclear | Quote: not mentioned Comment: unclear |
| Blinding of participants and personnel (performance bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Blinding of outcome assessment (detection bias)All outcomes | Low risk  | Quote: not mentionedComment: mortality and survival is an objective parameter. Subjective judgement can not influent the result. |
| Incomplete outcome data (attrition bias)All outcomes | Unclear | Quote: not mentionedComment: unclear |
| Selective reporting (reporting bias) | Low risk | The primary outcome listed in the method section are all reportedComment: probably done |
| Other bias | Unclear  | The study did not use the intention to treat strategy to analyze the result |

**Table 25 Characteristics of included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Studies | Age | Sex (male:female) | Race | Disease | No. of participants (TCM: control) | Intervention | **Published language** |
| TCM | Controll |
| Dian Rong 2009[15,21,25,,31,33] | TCM 39.52 ± 18.87Control 37.94 ± 18.55 | TCM 50:21Control 39:27 | Chinese | Acute leukemia | 71:66 | Compound Zhe Bei granule+standard chemotherapy | Placebo + standard chemotherapy | English |
| Mao Sheng 2007[26,27] | TCM 35. 63 ± 6. 46Control 36.57 ± 7.38 | TCM 33:27Control 31:29 | Chinese | Acute myeloid leukemia | 60:60 | Yi Qi Jie Du Huo Xue decoction + standard western mechicine | standard western mechicine | Chinese |
| sHai Yan 2007[22] | TCM 18-65Control 19-63 | TCM 5:3Control 7:3 | Chinese | Chronic myelogenous leukemia | 8:10 | Qu Du Hua Yu decoction + hydroxyurea | hydroxyurea | Chinese |
| sWei Hong 2013[23] | TCM 25-60Control 25-65 | TCM 22:14Control 17:7 | Chinese | Chronic myelogenous leukemia | 22:17 | TCM + interferon-a | interferon-a | Chinese |
| Chuan Xin 2013[32] | TCM 4.30 ± 1.81Control 4.95 ± 2.04 | TCM 12:8Control 10:10 | Chinese | Pediatric acute myeloid leukemia | 20:20 | TCM + standard chemotherapy | standard chemotherapy | Chinese |
| Ji Hong 2011[34] | TCM 60-71Control 61-72 | TCM 16:16Control 15:13 | Chinese | Elderly acute myeloid leukemia | 32:28 | TCM + HAG chemotherapy | HAG chemotherapy | Chinese |
| Rui Rong 2004[29] | TCM 12-78Control 11-76 | TCM 40:28Control 27:19 | Chinese | Acute myeloid leukemia | 68:46 | TCM + standard chemotherapy | standard chemotherapy | Chinese |
| Su Juan 2005[24] | TCM 32.5 ± 12.45Control 31.53 ± 12.41 | TCM 16:14Control 17:13 | Chinese | Acute leukemia | 30:30 | Qing Re Jie Du kang Bai decoction + standard chemotherapy | standard chemotherapy | Chinese |
| Wen Jiang 2010[30] | TCM 47-78Control 46-79 | TCM 17:12Control 15:13 | Chinese | Acute myeloid leukemia | 29:28 | Shen Qi Qing Re Ke Li + HAG chemotherapy | HAG chemotherapy | Chinese |
| Xiu Mei 1997[35] | TCM 6-73Control 6-71 | TCM 72:40Control 36:19 | Chinese | Non-Hodgkin lymphoma | 112:55 | TCM+standard chemotherapy | standard chemotherapy | Chinese |
| Ying Fei 2005[28] | TCM 13-72Control 15-71 | TCM 22:10Control 25:8 | Chinese | Acute leukemia | 32:33 | Shen Qi Fu Zheng injection+standard chemotherapy | standard chemotherapy | Chinese |

TCM: Traditional Chinese medicine,

**Table 26 Quality assessment of included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Studies | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias)All outcomes | Blinding of outcome assessment (detection bias)All outcomes | Incomplete outcome data (attrition bias)All outcomes | Selective reporting (reporting bias) | **Other bias** |
| Dian Rong 2009[15,21,25,,31,33] | Low risk | Unclear | Low risk | Low risk | Unclear | Low risk | Unclear |
| Mao Sheng 2007[26,27] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |
| sHai Yan 2007[22] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |
| sWei Hong 2013[23] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |
| Chuan Xin 2013[32] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |
| Ji Hong 2011[34] | Low risk | Unclear | Unclear | Low risk | Low risk | Low risk | Unclear |
| Rui Rong 2004[29] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |
| Su Juan 2005[24] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |
| Wen Jiang 2010[30] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |
| Xiu Mei 1997[35] | Low risk | Unclear | Unclear | Unclear | Unclear | Low risk | Unclear |
| Ying Fei 2005[28] | Low risk | Unclear | Unclear | Low risk | Unclear | Low risk | Unclear |

**Table 27 Summary of findings of the overall response and complete response outcomes**

|  |
| --- |
| **Overall reponse rate for Malignant hematologic disease** |
| **Patient or population:** patients with Malignant hematologic disease**Settings:** **Intervention:** overall reponse rate |
| **Outcomes** | **Illustrative comparative risksa (95% CI)** | **Relative effect(95% CI)** | **No. of participants(studies)** | **Quality of the evidence(GRADE)** | **Comments** |
| Assumed risk | Corresponding risk |
|  | **Control** | **Overall reponse rate** |  |  |  |  |
| **overall response rate** | **Study population** | **RR 1.14** (1.03 to 1.26) | 974(12 studies) | ⊕⊕⊝⊝**low** |  |
| **761 per 1000** | **867 per 1000**(784 to 959) |
| **Moderate** |
| **775 per 1000** | **883 per 1000**(798 to 976) |
| **complete response rate** | **Study population** | **RR 1.21** (1 to 1.46) | 974(12 studies) | ⊕⊕⊝⊝**low**1,2 |  |
| **579 per 1000** | **701 per 1000**(579 to 846) |
| **Moderate** |
| **579 per 1000** | **701 per 1000**(579 to 845) |
| aThe basis for the assumed risk (*e.g.*, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 1Not all studies included were high quality randomized controlled trial; 2Most studies showed better effect when traditional Chinese medicine was added while some studies did not show statistically significant better effect. GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality: We are very uncertain about the estimate. RR: Risk ratio. |
|  |